


**A Study of the role of Bezafibrate
in the treatment of
Neonatal Indirect Hyperbilirubinaemia**

THESIS

**Submitted for the partial fulfillment of the
M.Sc. Degree in Pediatrics**



618.9201
R. A

**By
Reham Aly Ammar
M.B., B.Ch.**

57845

Under the supervision of

Prof. Dr. Hamed Mahmoud Shatla

Prof. Dr. Mohamed Hamza El-Ahl

**Professor of Pediatrics
Faculty of Medicine
Ain Shams University**

**Professor of Pediatrics
Military Medical Academy**

Dr. Mamdouh Abdel Maksoud Mohamed

**Lecturer of Pediatrics
Faculty of Medicine
Ain Shams University**



Handwritten signature/initials.

**Faculty of Medicine
Ain Shams University
1994**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ ①
الْحَمْدُ لِلَّهِ رَبِّ الْعَالَمِينَ ②
الرَّحْمَنِ الرَّحِيمِ ③ مَلِكِ يَوْمِ الدِّينِ ④
إِيَّاكَ نَعْبُدُ وَإِيَّاكَ نَسْتَعِينُ ⑤ أَهْدِنَا
الصِّرَاطَ الْمُسْتَقِيمَ ⑥ صِرَاطَ الَّذِينَ أَنْعَمْتَ
عَلَيْهِمْ غَيْرِ الْمَغْضُوبِ عَلَيْهِمْ
وَلَا الضَّالِّينَ ⑦



CONTENTS

	Page
ACKNOWLEDGMENT	v i
LIST OF ABBREVIATIONS	viii
LIST OF FIGURES	xi
LIST OF TABLES	x v
I. INTRODUCTION AND AIM OF WORK	1
II. REVIEW OF LITERATURE	4
<u>Chapter One : Biophysiology of Bilirubin</u>	<u>5</u>
- Sources of Bilirubin.	5
- Transport of Bilirubin in The Circulation.	7
- Hepatic Uptake of Bilirubin .	8
- Conjugation of Bilirubin in The Liver.	9
- The Entro-Hepatic Circulation .	1 1
<u>Chapter Two : Neonatal Hyperbilirubinaemia</u>	<u>1 5</u>
- Definition.	1 5
- Causes of Neonatal Hyperbilirubinaemia.	1 5
- Unconjugated Hyperbilirubinaemia.	2 3
1) Physiological Jaundice.	2 3
2) Pathological Jaundice in The Newborn.	2 7
A. Isoimmune Haemolytic Disease of	
The New born.	2 7
B. Structural Defects of The Erythro-	

	Page
cyte Membrane.	3 3
C. Red Cell Enzymopathies.	3 4
D. The Familial Non-Haemolytic Un- conjugated Hyperbilirubinaemias.	3 9
E. Acquired Disorders in Bilirubin Metabolism.	4 2
- Toxicity of Unconjugated Bilirubin (Kernicterus).	5 7
- Diagnosis of Neonatal Jaundice.	6 6
- Management of Neonatal Jaundice.	7 9
A. Phototherapy.	8 2
B. Exchange Transfusion.	1 0 0
C. Drug Therapies Used in Neonatal Hyperbilirubinaemia.	1 0 7
D. Other Methods of Management.	1 1 0
<u>Chapter Three : Bezafibrate Treatment of Neonatal Jaundice</u>	1 1 2
* Pharmacological Introduction.	1 1 2
- Mechanism of Action.	1 1 4
- Absorption, Fate And Excretion.	1 1 5
- Adverse Effects And Drug Interactions.	1 1 5
- Preparations, Dosage, And Therapeutic	

	Page
Uses.	1 1 7
* Clofibrate And Neonatal Jaundice.	1 1 9
III. SUBJECTS AND METHODS.	1 2 4
IV. RESULTS.	1 3 0
V. DISCUSSION.	1 8 3
VI. SUMMARY AND CONCLUSION.	1 9 3
VII. REFERENCES.	1 9 7
VIII. ARABIC SUMMARY.	2 4 1

ACKNOWLEDGMENT

FIRST AND FOREMOST, THANKS TO GOD.

It has been a great honor and extreme pleasure for me to perform this study under the supervision of **PROF. DR. HAMED MAHMOUD SHATLA**, Professor of Paediatrics, Faculty of Medicine, Ain Shams University. I am extremely indebted to him, for his constant supervision, fatherly encouragement and kind support in this work. His kind guidance and valuable advice have been of extreme help in the completion of this work in its present form.

I am extremely grateful to **PROF. DR. MOHAMMED HAMZA SAYED EL-AHL**, Professor of Paediatrics, Military Medical Academy, for his constant supervision and enthusiastic encouragement in this work, providing me with the facilities needed to accomplish this study, and offering his most valuable advice and guidance. To him I am sincerely thankful.

I would like to thank **DR. MAMDOUH ABDEL MAKSOUD MOHAMMED**, Lecturer of Paediatrics, Ain Shams University, Faculty of Medicine, who devoted much of his time and spent tremendous effort guiding me through this work and revising all the minute details. For his generous aid and enthusiasm, I am deeply grateful.

I would like also to thank **DR. TALAL ABDEL AZIZ**, Chairman of Paediatric Department in Ghamra Military Hospital, who gave me a great help by offering me his most precious advice and guidance and providing me with many facilities for the completion of this work.

I cannot find adequate words to express my sincere gratitude and deep indebtedness to **MY PARENTS AND MY HUSBAND** for their constant support, loving, encouragement and genuine concern throughout this study. Without them, I could never have done it. A very special word of thanks to my father, who sacrificed much of his time helping me in organizing my work; for his help I can never thank him enough.

Last but not least, I would like to thank every person who gave me a hand during the completion of this work, whether by supplying references, helping in sample-gathering, performing lab. tests, providing moral support or aiding in any other way. To all of them, I am humbly thankful.

The Candidate

LIST OF ABBREVIATIONS

α	Alpha
β	Beta
δ	Delta
γ	Gamma
&	And
C ^o	Degree Centigrade
<	Less Than
≤	Less or Equal
>	More Than
≥	More or Equal
%	Percent
No.	Number
ACD	Acid - Citrate - Dextrose
ADSOL	Albumin Depleting Solution
AIHA	Auto immune Hemolytic Anaemia
ATP	Adenosine Triphosphate
BGT	Bilirubin Glucuronyl Transferase
BSP	Bromosulphalein
CBC	Complete Blood Count
CK	Creatin Kinase
cm	Centimeter
CPD	Citrate - Phosphate Dextrose
d.t.	Due to

DIC	Disseminated Intravascular Coagulation
FFA	Free Fatty Acids
Fig	Figure
G6PD	Glucose 6 phosphate Dehydrogenase
gm	Gram
GSH	Reduced Glutathione
Hb	Haemoglobin
HDL	High Density Lipoprotein
HE	Hereditary Elliptocytosis
HS	Hereditary Spherocytosis
i.u	International Unit
I.V.	Intravenous
ICG	Indocyanine Green
IDL	Intermediate Density Lipoprotein
Ig	Immunoglobulin
IVGG	Intravenous Gamma Globulin
LBW	Low Birth weight
LDL	Low Density Lipoprotein
MDF	Maximum Displacement Factor
mg	Milligram
nm	Nanometer
OH ⁻	Hydroxyl Group
PH	Power Of Hydrogen Ions
PK	Pyruvate Kinase
PMNLs	Polymorphonuclear Leucocytes
RB	Rose Bengal

RBCs	Red Blood Cells
RES	Reticuloendothelial System
TORCH	Toxoplasmosis, Rubella, Cytomegalovirus, and Herpes Virus
UCB	Unconjugated Bilirubin
UDP	Uridine Diphosphate
UDPGT	Uridine Diphosphoglucuronyl-Transferase
ug/dl	Microgram per Deciliter
uw	Microwatts
VLDL	Very Low Density Lipoprotein
Vs	Versus
Zn	Zinc

LIST OF FIGURES

		Page
<u>Section II</u>		
Fig. II 1.1	Schematic representation of the microsomal heme oxygenase system.	6
Fig. II 1.2	Conjugation of bilirubin with glucuronic acid.	10
Fig. II 1.3	The pathway of bilirubin productions, transport and metabolism.	12
Fig. II 1.4	Bilirubin metabolism in the Newborn.	14
Fig. II 2.1	Glutathione in the RBC.	35
Fig. II 2.2	Mechanism of haemolysis in G6PD Deficiency.	36
Fig. II 2.3	Natural history of jaundice in white breast-fed and formula-fed infants.	44
Fig. II 2.4	Kramer's rule for clinical assessment of neonatal jaundice.	66
Fig. II 2.5	Diagnosis of aetiology of hyperbiliubinaemia.	74
Fig. II 2.6	Management of neonatal jaundice.	80
Fig. II 2.7	Molecular formula of bilirubin IX α .	83
Fig. II 3.1	Structural formulae of Fibric acids.	113

Section IV

Fig. IV 1	Comparison of mean body weight between nonhaemolytic neonates in the three methods of treatment.	148
Fig. IV 2	Comparison of mean body weight between haemolytic neonates in two methods of treatment.	148
Fig. IV 3	Comparison of mean gestational age between non haemolytic neonates in the three methods of treatment.	151
Fig. IV 4	Comparison of mean gestational age between haemolytic neonates in two methods of treatment.	151
Fig. IV 5	Comparison of mean neonatal age between nonhaemolytic neonates in the three methods of treatment.	154
Fig. IV 6	Comparison of mean neonatal age between haemolytic neonates in two methods of treatment.	154
Fig. IV 7	Percent incidence of sex distribution between nonhaemolytic neonates in the three methods of treatment.	157
Fig. IV 8	Percent incidence of sex distribution between haemolytic neonates in two	

	Page
	157
Fig. IV 9	158
Fig. IV 10	159
Fig. IV 11	161
Fig. IV 12	162
Fig. IV 13	168
Fig. IV 14	171
Fig. IV 15	172
Fig. IV 16	173

	Page
Fig. IV 17	Percent reduction in bilirubin of groups A, B and C nonhaemolytic neonates after treatment. 174
Fig. IV 18	percent reduction in bilirubin of groups B and C neonates after treatment. 175
Fig. IV 19	Percent reduction in bilirubin of total groups A, B and C neonates after treatment. 176
Fig. IV 20	Mean phototherapy duration of non-haemolytic neonates in groups B and C.177
Fig. IV 21	Correlation trend for group A neonates.180
Fig. IV 22	Correlation trend for group B neonates.181
Fig. IV 23	Correlation trend for group C neonates.182